T1	CHEM 1965 1969	FAME
#1	AnnotatorNotes T1	C0242708; Antirheumatic Drugs, Disease-Modifying; Pharmacologic Substance
T2	PROC 79 86	placebo
#2	AnnotatorNotes T2	C0032042; Placebos; Therapeutic or Preventive Procedure
T3	CHEM 93 103	adalimumab
#3	AnnotatorNotes T3	C1122087; adalimumab; Amino Acid, Peptide, or Protein · Immunologic Factor · Pharmacologic Substance
T4	DISO 121 140	artritis psoriásica
#4	AnnotatorNotes T4	C0003872; Arthritis, Psoriatic; Disease or Syndrome
T5	CHEM 191 247	fármaco modificador de la enfermedad (FAME) no biológico
#5	AnnotatorNotes T5	C4054347; Non-Biologic Disease-Modifying Antirheumatic Drug; Pharmacologic Substance
T7	PROC 269 310	Estudio fase 3, aleatorizado, doble ciego
T8	PROC 336 343	placebo
#6	AnnotatorNotes T8	C0032042; Placebos; Therapeutic or Preventive Procedure
T9	CHEM 350 360	adalimumab
#7	AnnotatorNotes T9	C1122087; adalimumab; Amino Acid, Peptide, or Protein · Immunologic Factor · Pharmacologic Substance
T10	DISO 378 397	artritis psoriásica
#8	AnnotatorNotes T10	C0003872; Arthritis, Psoriatic; Disease or Syndrome
T11	DISO 802 805	APs
#9	AnnotatorNotes T11	C0003872; Arthritis, Psoriatic; Disease or Syndrome
T12	DISO 558 561	PsA
#10	AnnotatorNotes T12	C0003872; Arthritis, Psoriatic; Disease or Syndrome
T13	CHEM 468 524	fármaco modificador de la enfermedad (FAME) no biológico
#11	AnnotatorNotes T13	C4054347; Non-Biologic Disease-Modifying Antirheumatic Drug; Pharmacologic Substance
T14	DISO 934 937	APs
#12	AnnotatorNotes T14	C0003872; Arthritis, Psoriatic; Disease or Syndrome
T15	DISO 529 548	artritis psoriásica
#13	AnnotatorNotes T15	C0003872; Arthritis, Psoriatic; Disease or Syndrome
T16	CHEM 1358 1377	FAMEs no biológicos
#14	AnnotatorNotes T16	C4054347; Non-Biologic Disease-Modifying Antirheumatic Drug; Pharmacologic Substance
T17	DISO 586 605	Artritis Psoriásica
#15	AnnotatorNotes T17	C0003872; Arthritis, Psoriatic; Disease or Syndrome
T18	DISO 631 650	Artritis psoriásica
#16	AnnotatorNotes T18	C0003872; Arthritis, Psoriatic; Disease or Syndrome
T19	PROC 779 798	Diagnóstico clínico
#17	AnnotatorNotes T19	C0332140; Diagnosis, clinical; Diagnostic Procedure
T20	DISO 824 832	síntomas
#18	AnnotatorNotes T20	C1457887; Symptoms; Sign or Symptom
T21	DISO 951 961	Enfermedad
#19	AnnotatorNotes T21	C0012634; Disease; Disease or Syndrome
T22	DISO 1025 1049	articulaciones doloridas
T23	ANAT 1073 1087	articulaciones
#20	AnnotatorNotes T23	C0022417; Joints; Body Space or Junction | C1269611; Entire joint; Body Space or Junction
T24	ANAT 1099 1113	articulaciones
#21	AnnotatorNotes T24	C0022417; Joints; Body Space or Junction | C1269611; Entire joint; Body Space or Junction
T25	DISO 1099 1129	articulaciones con tumefacción
T26	ANAT 1153 1167	articulaciones
#22	AnnotatorNotes T26	C0022417; Joints; Body Space or Junction | C1269611; Entire joint; Body Space or Junction
T27	PROC 1209 1220	Diagnóstico
#23	AnnotatorNotes T27	C0011900; Diagnosis; Diagnostic Procedure
T28	DISO 1224 1243	psoriasis en placas
#24	AnnotatorNotes T28	C0263361; Psoriasis vulgaris; Disease or Syndrome
T29	CHEM 1521 1524	LEF
T30	CHEM 1538 1549	bucillamina
T31	DISO 1277 1296	psoriasis en placas
#25	AnnotatorNotes T31	C0263361; Psoriasis vulgaris; Disease or Syndrome
T32	PROC 1329 1353	tratamiento concomitante
#26	AnnotatorNotes T32	C1707479; Concomitant Therapy; Therapeutic or Preventive Procedure
T33	PROC 1442 1453	tratamiento
#27	AnnotatorNotes T33	C0087111; Therapeutic procedure; Therapeutic or Preventive Procedure
T34	CHEM 1511 1514	MTX
#28	AnnotatorNotes T34	C0025677; methotrexate; Organic Chemical · Pharmacologic Substance
T35	CHEM 1526 1536	apremilast
#29	AnnotatorNotes T35	C1678805; apremilast; Organic Chemical · Pharmacologic Substance
T36	DISO 1576 1588	intolerancia
#30	AnnotatorNotes T36	C0277585; Intolerance to drug; Pathologic Function
T37	CHEM 1552 1562	iguratimod
T38	DISO 1710 1719	erosiones
#31	AnnotatorNotes T38	C1959609; Erosion lesion; Pathologic Function
T39	PROC 1752 1758	hs-CRP
#32	AnnotatorNotes T39	C4763419; High Sensitivity C-Reactive Protein Measurement; Laboratory Procedure
T40	CHEM 1861 1889	inhibidor de las janocinasas
T41	PROC 1899 1910	Tratamiento
#33	AnnotatorNotes T41	C0087111; Therapeutic procedure; Therapeutic or Preventive Procedure
T42	CHEM 1983 1986	MTX
#34	AnnotatorNotes T42	C0025677; methotrexate; Organic Chemical · Pharmacologic Substance
T43	CHEM 2051 2054	MTX
#35	AnnotatorNotes T43	C0025677; methotrexate; Organic Chemical · Pharmacologic Substance
T44	CHEM 67 74	ABT-494
#36	AnnotatorNotes T44	C4308782; ABT-494; Organic Chemical · Pharmacologic Substance
T45	CHEM 1931 1949	FAME no biológicos
#37	AnnotatorNotes T45	C4054347; Non-Biologic Disease-Modifying Antirheumatic Drug; Pharmacologic Substance
T46	CHEM 324 331	ABT-494
#38	AnnotatorNotes T46	C4308782; ABT-494; Organic Chemical · Pharmacologic Substance
T48	CHEM 1516 1519	SSZ
T49	ANAT 1025 1039	articulaciones
#39	AnnotatorNotes T49	C0022417; Joints; Body Space or Junction | C1269611; Entire joint; Body Space or Junction
T50	CHEM 1492 1509	FAME no biológico
#40	AnnotatorNotes T50	C4054347; Non-Biologic Disease-Modifying Antirheumatic Drug; Pharmacologic Substance
T51	CHEM 1623 1627	FAME
#41	AnnotatorNotes T51	C0242708; Antirheumatic Drugs, Disease-Modifying; Pharmacologic Substance
T52	CHEM 1988 1991	SSZ
T53	CHEM 1993 1996	LEF
T54	CHEM 1998 2009	aprernilast
T55	CHEM 2011 2014	HCQ
T56	CHEM 2016 2027	bucillamina
T57	CHEM 2030 2040	iguratimod
T58	CHEM 2074 2077	LEF
T59	CHEM 1891 1894	JAK
#42	AnnotatorNotes T59	C0597721; Janus kinase; Amino Acid, Peptide, or Protein · Enzyme
T60	Date 12 16	2016
T61	LIVB 107 116	pacientes
#43	AnnotatorNotes T61	C0030705; Patients; Patient or Disabled Group
T63	LIVB 364 373	pacientes
#44	AnnotatorNotes T63	C0030705; Patients; Patient or Disabled Group
T66	LIVB 714 739	Varones o mujeres adultos
#45	AnnotatorNotes T66	C0025266; Male population group; Population Group + C0043210; Woman; Population Group + C0001675; Adult; Age Group
T67	Age 760 767	18 años
T68	Duration 833 849	al menos 6 meses
T69	LIVB 1304 1312	paciente
#46	AnnotatorNotes T69	C0030705; Patients; Patient or Disabled Group
T71	LIVB 1385 1394	pacientes
#47	AnnotatorNotes T71	C0030705; Patients; Patient or Disabled Group
T73	Date 1911 1917	actual
T62	Neg_cue 1970 1982	distintos de
T64	DISO 217 227	enfermedad
#48	AnnotatorNotes T64	C0012634; Disease; Disease or Syndrome
T65	DISO 494 504	enfermedad
#49	AnnotatorNotes T65	C0012634; Disease; Disease or Syndrome
T6	PROC 1732 1749	radiográficamente
#50	AnnotatorNotes T6	C1306645; Plain x-ray; Diagnostic Procedure
T47	PROC 862 881	visita de Selección
#51	AnnotatorNotes T47	C1710477; Trial Screening; Research Activity + C1512346; Patient Visit; Health Care Activity
T70	PROC 1176 1196	visitas de Selección
#52	AnnotatorNotes T70	C1710477; Trial Screening; Research Activity + C1512346; Patient Visit; Health Care Activity
T72	Quantifier_or_Qualifier 1199 1204	Basal
A1	Population_data T66 Age
A2	Assertion T42 Negated
A3	Assertion T52 Negated
A4	Assertion T53 Negated
A5	Assertion T54 Negated
A6	Assertion T55 Negated
A7	Assertion T56 Negated
A8	Assertion T57 Negated
A9	Status T40 History_of
A10	Status T59 History_of
A11	Status T13 History_of
A12	Status T33 History_of
A13	Status T50 History_of
A14	Assertion T51 Contraindicated
A15	Status T34 History_of
A16	Status T48 History_of
A17	Status T29 History_of
A18	Status T35 History_of
A19	Status T30 History_of
A20	Status T37 History_of
#54	AnnotatorNotes T7	C0282461; Phase 3 Clinical Trials; Research Activity + C0034656; Randomization; Research Activity + C0013072; Double-Blind Method; Research Activity
#55	AnnotatorNotes T25	C0152031; Joint swelling; Finding
#56	AnnotatorNotes T30	C0073917; bucillamine; Organic Chemical · Pharmacologic Substance 
#57	AnnotatorNotes T37	C1872427; iguratimod; Organic Chemical · Pharmacologic Substance 
#58	AnnotatorNotes T40	C3854325; Janus kinase inhibitor; Pharmacologic Substance 
#59	AnnotatorNotes T73	C0521116; Current (present time); Temporal Concept 
#60	AnnotatorNotes T54	C1678805; apremilast; Organic Chemical · Pharmacologic Substance
#61	AnnotatorNotes T56	C0073917; bucillamine; Organic Chemical · Pharmacologic Substance
#62	AnnotatorNotes T57	C1872427; iguratimod; Organic Chemical · Pharmacologic Substance
T74	Quantifier_or_Qualifier 238 247	biológico
A21	Assertion T74 Negated
#53	AnnotatorNotes T74	C0205460; biological; Qualitative Concept
T75	Quantifier_or_Qualifier 515 524	biológico
A22	Assertion T75 Negated
#63	AnnotatorNotes T75	C0205460; biological; Qualitative Concept
T76	Neg_cue 512 514	no
T77	Neg_cue 235 237	no
T78	Neg_cue 1364 1366	no
T79	Quantifier_or_Qualifier 1367 1377	biológicos
A23	Assertion T79 Negated
#64	AnnotatorNotes T79	C0205460; biological; Qualitative Concept
T80	Neg_cue 1497 1499	no
T81	Quantifier_or_Qualifier 1500 1509	biológico
A24	Assertion T81 Negated
#65	AnnotatorNotes T81	C0205460; biological; Qualitative Concept
T82	Neg_cue 1936 1938	no
T83	Quantifier_or_Qualifier 1939 1949	biológicos
A25	Assertion T83 Negated
#66	AnnotatorNotes T83	C0205460; biological; Qualitative Concept
R2	Negation Arg1:T77 Arg2:T74	
R3	Negation Arg1:T76 Arg2:T75	
R4	Negation Arg1:T78 Arg2:T79	
R5	Negation Arg1:T80 Arg2:T81	
R6	Negation Arg1:T82 Arg2:T83	
R7	Negation Arg1:T62 Arg2:T42	
R8	Negation Arg1:T62 Arg2:T52	
R9	Negation Arg1:T62 Arg2:T53	
R10	Negation Arg1:T62 Arg2:T54	
R11	Negation Arg1:T62 Arg2:T55	
R12	Negation Arg1:T62 Arg2:T56	
R13	Negation Arg1:T62 Arg2:T57	
R14	Combined_with Arg1:T43 Arg2:T58	
R15	Experiences Arg1:T61 Arg2:T44	
R16	Experiences Arg1:T61 Arg2:T4	
T84	Observation 156 176	respuesta inadecuada
#67	AnnotatorNotes T84	C0858218; Inappropriate drug response; Finding
R17	Overlap Arg1:T84 Arg2:T5	
R18	Experiences Arg1:T61 Arg2:T64	
R19	Experiences Arg1:T61 Arg2:T84	
R20	Experiences Arg1:T61 Arg2:T5	
R21	Has_Quantifier_or_Qualifier Arg1:T5 Arg2:T74	
T85	Quantifier_or_Qualifier 179 190	al menos un
R22	Has_Quantifier_or_Qualifier Arg1:T5 Arg2:T85	
T86	Quantifier_or_Qualifier 456 467	al menos un
R23	Has_Quantifier_or_Qualifier Arg1:T13 Arg2:T86	
R24	Experiences Arg1:T63 Arg2:T46	
R25	Experiences Arg1:T63 Arg2:T10	
T87	Observation 433 453	respuesta inadecuada
A26	Status T87 History_of
#68	AnnotatorNotes T87	C0858218; Inappropriate drug response; Finding
R26	Experiences Arg1:T63 Arg2:T87	
R27	Overlap Arg1:T87 Arg2:T13	
R28	Has_Quantifier_or_Qualifier Arg1:T13 Arg2:T75	
R29	Experiences Arg1:T63 Arg2:T13	
R30	Experiences Arg1:T63 Arg2:T65	
R31	Experiences Arg1:T63 Arg2:T15	
R32	Experiences Arg1:T63 Arg2:T12	
R33	Experiences Arg1:T63 Arg2:T8	
R34	Experiences Arg1:T63 Arg2:T9	
R35	Experiences Arg1:T61 Arg2:T2	
R36	Experiences Arg1:T61 Arg2:T3	
R37	Before Arg1:T84 Arg2:T44	
R38	Before Arg1:T84 Arg2:T2	
R39	Before Arg1:T84 Arg2:T3	
R40	Before Arg1:T5 Arg2:T44	
R41	Before Arg1:T5 Arg2:T2	
R42	Before Arg1:T5 Arg2:T3	
R43	Before Arg1:T87 Arg2:T46	
R44	Before Arg1:T87 Arg2:T8	
R45	Before Arg1:T87 Arg2:T9	
R46	Before Arg1:T13 Arg2:T46	
R47	Before Arg1:T13 Arg2:T8	
R48	Before Arg1:T13 Arg2:T9	
T88	Quantifier_or_Qualifier 654 684	moderada a intensamente activa
#69	AnnotatorNotes T88	C1299393; Moderate to severe; Qualitative Concept + C0205177; Active; Qualitative Concept | C0679217; Active State; Idea or Concept
R49	Has_Quantifier_or_Qualifier Arg1:T18 Arg2:T88	
R50	Has_Age Arg1:T66 Arg2:T67	
R51	Causes Arg1:T11 Arg2:T20	
R52	Overlap Arg1:T20 Arg2:T68	
R53	Before Arg1:T20 Arg2:T47	
T89	CONC 939 945	CASPAR
R54	Used_for Arg1:T89 Arg2:T19	
R55	Causes Arg1:T14 Arg2:T20	
T90	Quantifier_or_Qualifier 962 968	activa
#70	AnnotatorNotes T90	C0205177; Active; Qualitative Concept | C0679217; Active State; Idea or Concept
R56	Has_Quantifier_or_Qualifier Arg1:T21 Arg2:T90	
T91	Quantifier_or_Qualifier 1017 1024	3 o más
R57	Location_of Arg1:T49 Arg2:T22	
R58	Has_Quantifier_or_Qualifier Arg1:T22 Arg2:T91	
R59	Location_of Arg1:T23 Arg2:T22	
T92	CONC 975 988	momento basal
#71	AnnotatorNotes T92	C1442488; Baseline; Quantitative Concept
R60	Overlap Arg1:T21 Arg2:T92	
#72	AnnotatorNotes T22	C0003862; Arthralgia; Sign or Symptom
T93	Quantifier_or_Qualifier 1091 1098	3 o más
R61	Location_of Arg1:T24 Arg2:T25	
R62	Has_Quantifier_or_Qualifier Arg1:T25 Arg2:T93	
R63	Location_of Arg1:T26 Arg2:T25	
R64	Overlap Arg1:T25 Arg2:T70	
T94	PROC 1176 1183	visitas
#73	AnnotatorNotes T94	C1512346; Patient Visit; Health Care Activity
R65	Has_Quantifier_or_Qualifier Arg1:T94 Arg2:T72	
R1	Overlap Arg1:T25 Arg2:T94	
R66	Overlap Arg1:T22 Arg2:T94	
R67	Overlap Arg1:T22 Arg2:T70	
R68	Causes Arg1:T21 Arg2:T22	
R69	Causes Arg1:T21 Arg2:T25	
#74	AnnotatorNotes T72	C1442488; Baseline; Quantitative Concept
T95	Quantifier_or_Qualifier 1244 1250	activa
#75	AnnotatorNotes T95	C0205177; Active; Qualitative Concept | C0679217; Active State; Idea or Concept
A27	Status T31 History_of
R70	Has_Quantifier_or_Qualifier Arg1:T28 Arg2:T95	
R71	Experiences Arg1:T69 Arg2:T32	
T96	Quantifier_or_Qualifier 1354 1357	≤ 2
R72	Has_Quantifier_or_Qualifier Arg1:T16 Arg2:T96	
R73	Has_Quantifier_or_Qualifier Arg1:T16 Arg2:T79	
R74	Used_for Arg1:T16 Arg2:T32	
T97	Observation 1418 1438	respuesta inadecuada
A28	Status T97 History_of
#76	AnnotatorNotes T97	C0858218; Inappropriate drug response; Finding
R75	Overlap Arg1:T97 Arg2:T33	
R76	Experiences Arg1:T71 Arg2:T97	
R77	Experiences Arg1:T71 Arg2:T33	
R78	Has_Quantifier_or_Qualifier Arg1:T50 Arg2:T81	
R79	Used_for Arg1:T50 Arg2:T33	
R80	Used_for Arg1:T34 Arg2:T33	
R81	Used_for Arg1:T48 Arg2:T33	
R82	Used_for Arg1:T29 Arg2:T33	
R83	Used_for Arg1:T35 Arg2:T33	
R84	Used_for Arg1:T30 Arg2:T33	
R85	Used_for Arg1:T37 Arg2:T33	
R86	Causes Arg1:T51 Arg2:T36	
R87	Experiences Arg1:T71 Arg2:T36	
#77	AnnotatorNotes T48	C0036078; sulfasalazine; Organic Chemical · Pharmacologic Substance
#78	AnnotatorNotes T29	C0063041; leflunomide; Organic Chemical · Pharmacologic Substance
T98	Quantifier_or_Qualifier 1700 1709	Una o más
R88	Has_Quantifier_or_Qualifier Arg1:T38 Arg2:T98	
T99	Result_or_Value 1759 1799	> límite superior de la normalidad (LSN)
R90	Has_Result_or_Value Arg1:T39 Arg2:T99	
T100	Quantifier_or_Qualifier 1922 1930	más de 2
R91	Has_Quantifier_or_Qualifier Arg1:T45 Arg2:T100	
R92	Has_Quantifier_or_Qualifier Arg1:T45 Arg2:T83	
R93	Used_for Arg1:T1 Arg2:T41	
R94	Used_for Arg1:T45 Arg2:T41	
R95	Overlap Arg1:T45 Arg2:T73	
R96	Overlap Arg1:T1 Arg2:T73	
R97	Used_for Arg1:T42 Arg2:T41	
R98	Used_for Arg1:T52 Arg2:T41	
R99	Used_for Arg1:T53 Arg2:T41	
R100	Used_for Arg1:T54 Arg2:T41	
R101	Used_for Arg1:T55 Arg2:T41	
R102	Used_for Arg1:T56 Arg2:T41	
R103	Used_for Arg1:T57 Arg2:T41	
R104	Used_for Arg1:T43 Arg2:T41	
R105	Overlap Arg1:T42 Arg2:T73	
R106	Overlap Arg1:T52 Arg2:T73	
R107	Overlap Arg1:T53 Arg2:T73	
R108	Overlap Arg1:T54 Arg2:T73	
R109	Overlap Arg1:T55 Arg2:T73	
R110	Overlap Arg1:T56 Arg2:T73	
R111	Overlap Arg1:T57 Arg2:T73	
R112	Overlap Arg1:T43 Arg2:T73	
R113	Overlap Arg1:T58 Arg2:T73	
#79	AnnotatorNotes T52	C0036078; sulfasalazine; Organic Chemical · Pharmacologic Substance
#80	AnnotatorNotes T53	C0063041; leflunomide; Organic Chemical · Pharmacologic Substance
#81	AnnotatorNotes T58	C0063041; leflunomide; Organic Chemical · Pharmacologic Substance
#82	AnnotatorNotes T55	C0020336; hydroxychloroquine; Organic Chemical · Pharmacologic Substance
#83	AnnotatorNotes T89	['ClASsification criteria for Psoriatic ARthritis']
A29	Experiencer T61 Patient
A30	Experiencer T63 Patient
A31	Experiencer T66 Patient
A32	Experiencer T69 Patient
A33	Experiencer T71 Patient
